+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 218 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
P

Actively Recruiting

Researchers are evaluating AV-380, an immunoglobulin G1 monoclonal antibody designed to bind human growth differentiation factor 15 GDF-15, a cytokine involved in cancer-induced cachexia. This phase 1B open-label dose escalation study aims to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of AV-380 in cancer patients who have cachexia and elevated GDF-15 levels. Participants have metastatic solid tumors and are actively receiving standard of care chemotherapy. Participants receive AV-380 through intravenous infusion in ascending dose cohorts alongside their standard chemotherapy treatments. The study includes a dose escalation phase where the safety and appropriate dosage of AV-380 are evaluated. This phase allows researchers to monitor the effects of increasing doses of AV-380 over a study period of up to 4 months while patients continue their usual cancer therapies. During the study, participants will undergo assessments including monitoring for adverse events, toxicity, and laboratory abnormalities from enrollment until about 60 days after the last dose. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, and area under the curve AUC will also be evaluated. The total involvement includes regular evaluations to track safety, drug behavior in the body, and immune responses to AV-380.

Age: 18Years +All GendersPhase 1
12 locations
L

Actively Recruiting

This research aims to evaluate the long-term effectiveness of mirikizumab in children and adolescents aged 2 to 19 years with moderate-to-severe ulcerative colitis or Crohns disease. The study is a phase 3, open-label, multicenter trial focusing on the treatment of these inflammatory bowel diseases and is sponsored by Eli Lilly and Company. It addresses the need for ongoing management of these chronic conditions in pediatric populations. Participants receive mirikizumab by subcutaneous injection in doses tailored to their weight across multiple administrations. In cases where response is lost, intravenous rescue dosing is available. This long-term extension study may include up to 44 visits over about 172 weeks. Additional treatment could be accessible through a Continued Access Period after the main study. During the study, participants are closely monitored through clinical assessments including remission and response evaluations using established scores like the Modified Mayo Score for ulcerative colitis and the Pediatric Crohns Disease Activity Index for Crohns disease. Researchers also examine endoscopic and histologic remission, corticosteroid use, and inflammation markers such as C-reactive protein. Safety and efficacy are tracked throughout, with participants undergoing regular visits for evaluations and treatment administration for nearly three and a half years.

Age: 2Years - 19YearsAll GendersPhase 3
69 locations
E

Actively Recruiting

Researchers are evaluating a new digital tool called Prioritize Personalize Prescribe Exercise P3-EX designed to help clinicians prescribe customized exercise plans to patients with cardiovascular disease CVD risk factors such as obesity, hypertension, dyslipidemia, and diabetes. This pilot randomized controlled crossover trial aims to test the usability and satisfaction of P3-EX compared to a standard exercise prescription method called the American College of Sports Medicine Physical Activity Vital Sign ACSM-PAVS. Clinicians including physicians, physician assistants, and advanced practice registered nurses will recruit patients with CVD risk factors and deliver exercise prescriptions using either P3-EX or ACSM-PAVS in a random sequence crossover design. Patients will follow their assigned exercise program for 12 weeks with virtual weekly oversight from University of Connecticut Graduate Research Assistants. Each patient will receive an exercise information packet, virtual guidance visits, and weekly progressive exercise goals by email. Clinicians and patients will complete usability and satisfaction questionnaires within 48 hours after each exercise prescription delivery. Participants will attend in-person visits at the start and end of the study to assess cardiovascular health, physical activity levels using accelerometers, and exercise adherence recorded in self-report diaries. Blood tests for lipid and glucose profiles will be performed at local labs. The study measures feasibility and acceptability of P3-EX as the primary outcome, and explores changes in patient cardiovascular risk factors, physical activity, and exercise adherence as secondary outcomes. The total participation involves baseline assessments, 12 weeks of exercise intervention, and post-intervention evaluations.

Age: 18Years - 64YearsAll GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
O

Actively Recruiting

Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.

Age: 18Years +All Genders
101 locations
O

Actively Recruiting

Researchers are following participants with pediatric-onset hypophosphatasia HPP, a rare bone disease that begins in childhood, to understand how the treatment asfotase alfa works over time. This observational sub-study will track patients at various sites in the United States and possibly other countries for at least five years, focusing on how the body responds to the treatment and any immune-related issues that may affect its effectiveness. All participants will receive asfotase alfa given under standard care, typically as subcutaneous injections. Younger children under 2 years old are recommended to have clinic visits about every three months until they turn two, then about every six months afterward. The study monitors biochemical, clinical, imaging if needed, and quality of life outcomes related to HPP to understand the long-term effects of treatment. Participants will be regularly evaluated over a minimum five-year period, including assessments by their treating physicians to detect any loss of treatment effectiveness or serious immune-related side effects. Data collection will include clinical exams, laboratory tests, functional assessments, and quality of life questionnaires. The study aims to gather detailed information about treatment outcomes and safety in real-world settings over time.

All AgesAll Genders
12 locations
A

Actively Recruiting

This research aims to explore how therapy-related clonal hematopoiesis t-CH, a pattern of blood cell growth with certain genetic mutations, is connected to heart health in patients treated for classical Hodgkin Lymphoma during childhood or adolescence. It focuses on those who received anthracycline chemotherapy and investigates whether t-CH can help identify patients at risk for cardiovascular disease CVD after cancer treatment, including comparing those with and without heart problems using cardiac MRI. Participants undergo an observational study where blood samples are collected, surveys completed, cardiac MRI scans performed, and medical records reviewed. Archived blood samples may also be collected if available. The study evaluates the prevalence and changes over time of t-CH mutations linked to heart disease and examines the relationship between clinical risk factors, treatment components, and the presence of cardiovascular disease in this patient group. During the study, participants provide blood samples and complete questionnaires while undergoing heart imaging to assess objective signs of heart disease. Researchers review medical records and analyze blood samples for genetic changes. The primary outcome measures include detecting t-CH mutations associated with heart disease within one year. Secondary outcomes assess the expansion of these mutations and their association with cardiovascular findings and patient variables. The study helps identify potential risk factors for heart complications among Hodgkin Lymphoma survivors treated with anthracyclines.

Age: 7Years +All Genders
36 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy approaches combined with standard surgery and radiation in patients newly diagnosed with intermediate-risk rhabdomyosarcoma. This phase III trial evaluates whether a higher dose chemotherapy over a shorter time performs better or differently than a lower dose chemotherapy with maintenance over a longer period. The study also examines survival rates, treatment side effects, and molecular features of the cancer. Participants are randomly assigned to one of two treatment regimens. Regimen A involves vincristine, dactinomycin, and a higher dose of cyclophosphamide given intravenously over multiple 21-day cycles, with possible surgery in week 12 and radiation during later cycles. Regimen B uses a lower cyclophosphamide dose alternating with vincristine and irinotecan, followed by 24 weeks of maintenance chemotherapy with vinorelbine and oral cyclophosphamide. Both groups undergo imaging scans and may have biopsies during the study. Throughout the trial, participants attend scheduled visits for chemotherapy administration, imaging CT, MRI, PET, blood and other sample collections, and monitoring of side effects. After treatment, follow-up visits occur every 3 months for the first year, then less frequently over 5 years. Researchers measure event-free survival, overall survival, local tumor control, treatment-related adverse events, and timely molecular biomarker reporting. Biospecimens are collected for future research and fertility preservation is assessed.

Age: 0 - 50YearsAll GendersPhase 3
87 locations
R

Actively Recruiting

Researchers are evaluating whether a personalized chemoradiation therapy approach, which may include a lower dose of radiation, is as effective as the standard chemoradiation therapy for people with HPV-positive throat cancer. This study also aims to assess if the lower radiation dose combined with standard chemotherapy results in fewer side effects and how these approaches impact participants quality of life through questionnaires. Participants will receive either a personalized radiation dose based on hypoxia status or the standard radiation dose. Those without hypoxia receive 30 Gy in 2 Gy fractions over 15 days with concurrent standard chemotherapy, while those with hypoxia or in the standard group receive 70 Gy in 2 Gy fractions over 35 days with concurrent chemotherapy. After treatment, a FDG PETCT scan is done around 4 months later to check for persistent disease, with surgery performed if needed, followed by additional standard care. During the study, participants will undergo an FMISO-PET scan during week two of radiation to assess hypoxia. Quality of life will be measured with questionnaires, and overall survival at 2 years is the primary outcome. Participants will be monitored through clinical assessments and imaging during and after treatment. The study is expected to complete by August 2027.

Age: 18Years +All GendersPhase 3
9 locations

1-10 of 218

1